Participation of kinin receptors on memory impairment after chronic infusion of human amyloid-β 1-40 peptide in mice

被引:26
作者
Amaral, Fabio Agostini [1 ]
Resk Lemos, Mayra Tolentino [1 ]
Dong, Karis Ester [1 ]
Queiroz Prado Bittencourt, Maria Fernanda [1 ]
Caetano, Ariadiny Lima [1 ]
Pesquero, Joao Bosco [3 ]
Viel, Tania Araujo [2 ]
Buck, Hudson Sousa [1 ]
机构
[1] Fac Ciencies Med Santa Casa Sao Paulo, Dept Physiol Sci, BR-01221020 Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Arts Sci & Humanities, BR-03828000 Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biophys, BR-04023900 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Bradykinin; Alzheimer; Neurodegeneration; B1; receptor; B2; Neuroinflammation; ALZHEIMERS-DISEASE; BRADYKININ RECEPTOR; EXPRESSION CLONING; B-1; RECEPTORS; PROTEIN; BRAIN; PHARMACOLOGY; FIBROBLASTS; MECHANISMS; PRECURSOR;
D O I
10.1016/j.npep.2009.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic infusion of human amyloid-beta 1-40 (A beta) in the lateral ventricle (LV) of rats is associated with memory impairment and increase of kinin receptors in cortical and hippocampal areas. Deletion of kinin B1 or B2 receptors abolished memory impairment caused by an acute single injection of A beta in the LV. As brain tissue and kinin receptors could unlikely react to acute or chronic administration of a similar quantity of A beta, we evaluated the participation of B1 or B2 receptors in memory impairment after chronic infusion of A beta. Male C57BI/6 J (wt), knock-out B1 (koB1) or B2 (koB2) mice (12 weeks of age) previously trained in a two-way shuttle-box and achieving conditioned avoidance responses (CAR, % of 50 trials) were infused with AB (550 pmol, 0.12 mu L/h, 28 days) or vehicle in the LV using a mini-osmotic pump. They were tested before the surgery (TO), 7 and 35 days after the infusion started (T7; T35). In T0, no difference was observed between CAR of the control (Cwt = 59.7 +/- 6.7%; CkoB1 = 46.7 +/- 4.0%; CkoB2 = 64.4 +/- 5.8%) and A beta (A beta wt = 66.0 +/- 3.0%; A beta koB1 = 66.8 +/- 8.2%; A beta koB2 = 58.7 +/- 5.9%) groups. In T7, A beta koB2 showed a significant decrease in CAR (41.0 +/- 8.6%) compared to the control-koB2 (72.8 +/- 2.2%, P <0.05). In T35, a significant decrease (P <0.05) was observed in A beta wt (40.7 +/- 3.3%) and A beta koB2 (41.2 +/- 10.7%) but not in the A beta koB1 (64.0 +/- 14.0%) compared to their control groups. No changes were observed in the controls at T35. We suggest that in chronic infusion of BA, B1 receptors could playan important role in the neurodegenerative process. Conversely, the premature memory impairment of koB2 suggests that it may be a protective factor. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 26 条
[1]   Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension [J].
Duka, I ;
Kintsurashvili, E ;
Gavras, I ;
Johns, C ;
Bresnahan, M ;
Gavras, H .
CIRCULATION RESEARCH, 2001, 88 (03) :275-281
[2]   Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin [J].
Duka, I ;
Duka, A ;
Kintsurashvili, E ;
Johns, C ;
Gavras, I ;
Gavras, H .
HYPERTENSION, 2003, 42 (05) :1021-1025
[3]  
Frautschy SA, 1998, J NEUROSCI, V18, P8311
[4]  
HUANG HM, 1995, J NEUROCHEM, V64, P761
[5]   Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease [J].
Iores-Marcal, Ligia M. ;
Viel, Tania A. ;
Buck, Hudson Sousa ;
Nunes, Viviane A. ;
Gozzo, Andrezza J. ;
Cruz-Silva, Ilana ;
Miranda, Antonio ;
Shimamoto, Kazuaki ;
Ura, Nobuyuki ;
Araujo, Mariana S. .
PEPTIDES, 2006, 27 (12) :3363-3369
[6]   Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease [J].
Jong, YJI ;
Dalemar, LR ;
Seehra, K ;
Baenziger, NL .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (13-14) :1833-1840
[7]   Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation [J].
Jong, YJI ;
Ford, SR ;
Seehra, K ;
Malave, VB ;
Baenziger, NL .
FASEB JOURNAL, 2003, 17 (13) :2319-+
[8]   Interaction of Factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Aβ protein of Alzheimer' s disease [J].
Joseph, K ;
Shibayama, Y ;
Nakazawa, Y ;
Peerschke, EIB ;
Ghebrehiwet, B ;
Kaplan, AP .
IMMUNOPHARMACOLOGY, 1999, 43 (2-3) :203-210
[9]   International union of pharmacology.: XLV.: Classification of the kinin receptor family:: from molecular mechanisms to pathophysiological consequences [J].
Leeb-Lundberg, LMF ;
Marceau, F ;
Müller-Esterl, W ;
Pettibone, DJ ;
Zuraw, BL .
PHARMACOLOGICAL REVIEWS, 2005, 57 (01) :27-77
[10]  
LEMOS MTR, NEUROPEPTIDES UNPUB